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Nitric oxide (NO) and carbon monoxide (CO) are
gasotransmitters that suppress the development of
severe forms of malaria associated with Plasmodium
infection. Here, we addressed themechanism under-
lying their protective effect against experimental
cerebral malaria (ECM), a severe form of malaria
that develops in Plasmodium-infected mice, which
resembles, in many aspects, human cerebral malaria
(CM). NO suppresses the pathogenesis of ECM via a
mechanism involving (1) the transcription factor
nuclear factor erythroid 2-related factor 2 (NRF-2),
(2) induction of heme oxygenase-1 (HO-1), and
(3) CO production via heme catabolism by HO-1.
The protection afforded by NO is associated with in-
hibition of CD4+ T helper (TH) and CD8
+ cytotoxic (TC)
T cell activation in response to Plasmodium infection
via a mechanism involving HO-1 and CO. The protec-
tive effect of NO and CO is not associated with mod-
ulation of host pathogen load, suggesting that these
gasotransmitters establish a crosstalk-conferring
disease tolerance to Plasmodium infection.
INTRODUCTION
Plasmodium infection can lead to the development of cerebral
malaria (CM) (Mishra and Newton, 2009), an often-lethal
neurovascular syndrome, triggered by maladaptive host immu-
nity (Miller et al., 2013) and the sequestration of Plasmodium-
infected red blood cells (RBCs) in the brain microvasculature
(Taylor et al., 2004). These pathologic events lead to the disrup-
tion of the blood brain barrier (BBB), brain edema, and coma, the
hallmarks of CM (Mishra and Newton, 2009).
As for other clinical manifestations ofmalaria, CMarises exclu-
sively during the blood stage of Plasmodium infection (Miller126 Cell Reports 8, 126–136, July 10, 2014 ª2014 The Authorset al., 2013), associated with hemolysis and hence with the
generation of cell-free hemoglobin (Hb) (Andrade et al., 2010;
Ferreira et al., 2008; Francis et al., 1997). When oxidized into
(ferric) methemoglobin (MetHb), extracellular Hb releases its
prosthetic heme groups (Balla et al., 1993; Bunn and Jandl,
1968; Gozzelino et al., 2010). Free heme is proinflammatory (Fig-
ueiredo et al., 2007), cytotoxic (Balla et al., 1993; Gozzelino et al.,
2010; Seixas et al., 2009), and vasoactive (Belcher et al., 2014),
thus promoting the pathogenesis of experimental cerebral
malaria (ECM) (Ferreira et al., 2008, 2011; Pamplona et al.,
2007), a neurovascular syndrome that develops in Plasmodium
berghei ANKA (PbA)-infected mice and that resembles in many
aspects human CM that develops in response to P. falciparum
infection (Mishra and Newton, 2009).
The pathogenesis of ECM is fueled by the activation of CD4+ T
helper (TH) and CD8
+ cytotoxic T (TC) cells (Belnoue et al., 2002,
2008; Nitcheu et al., 2003; Villegas-Mendez et al., 2012) that
migrate into the brain microvasculature, via a mechanism
involving the expression of the chemokines CXCL9, CXCL-10/
IP10, and their cognate receptor CXCR3 (Campanella et al.,
2008; Miu et al., 2008). Interaction of activated TH and TC with
microvascular endothelial cells in the brain compromises BBB
integrity via a mechanism involving the expression of Perforin
(Prf) (Nitcheu et al., 2003) and granzyme B (GzmB) (Haque
et al., 2011) by activated TC cells. This cytotoxic effect syner-
gizes locally with free heme to trigger ECM (Ferreira et al.,
2008, 2011; Gozzelino et al., 2010).
Mammals have a variety of protective mechanisms restraining
the deleterious effects of heme, which converge at the level of
heme catabolism by heme oxygenase-1 (HO-1) (encoded by
the HMOX1 gene), generating equimolar amounts of carbon
monoxide (CO), labile Fe, and biliverdin (Tenhunen et al.,
1968). Induction of HO-1 expression in response to Plasmodium
infection suppresses the pathogenesis of ECM (Ferreira et al.,
2008, 2011; Pamplona et al., 2007) as well as the pathogenesis
of noncerebral forms of severe malaria in mice (Ferreira et al.,
2008; Seixas et al., 2009). This protective effect is not associated
with modulation of host pathogen load, thus suggesting that
HO-1 does not regulate host resistance to Plasmodium infection.
Instead, HO-1 limits tissue damage imposed to the host during
infection, suggesting that it confers disease tolerance (Ayres
and Schneider, 2012; Medzhitov et al., 2012; Schneider and
Ayres, 2008) to Plasmodium infection. In contrast to resistance
to infection, disease tolerance limits disease severity (Schneider,
2011) via a mechanism that does not necessarily impact on the
host pathogen load (Medzhitov et al., 2012; Schneider and
Ayres, 2008). In keeping with this notion, the survival advantage
afforded by sickle Hb against malaria acts via a mechanism that
involves the induction of HO-1, conferring disease tolerance to
Plasmodium infection (Ferreira et al., 2011). Moreover, polymor-
phisms in the HMOX1 gene correlate with incidence of severe
forms of malaria in human populations (Andrade et al., 2010),
including CM (Walther et al., 2012). Overall, this argues strongly
for the involvement of HO-1 in the regulation of disease severity
in response to Plasmodium infection in mice as well as in
humans.
CO contributes critically to the protective effect of HO-1
against ECM (Ferreira et al., 2008, 2011; Pamplona et al.,
2007). This salutary effect relies on the avid binding of CO to
the prosthetic heme groups of cell-free Hb and the formation
of a not readily oxidized carboxyhemoglobin (CO-Hb) complex
(Hebbel et al., 1988; Pamplona et al., 2007). This antioxidant
effect restrains the pathogenic effects of cell-free Hb (Silva
et al., 2009) and prevents the proinflammatory (Figueiredo
et al., 2007) and cytotoxic (Gozzelino et al., 2010; Larsen et al.,
2010; Seixas et al., 2009) effects associated with heme release
from Hb, from partaking in the pathogenesis of ECM.
Cell-free Hb also contributes to pathogenesis of severe forms
ofmalaria via nitric oxide (NO) scavenging, reducing NObioavail-
ability (Rother et al., 2005; Gramaglia et al., 2006) and promoting
brain microvascular constriction associated with the pathogen-
esis of ECM (Cabrales et al., 2011; Gramaglia et al., 2006; Ong
et al., 2013). That NO regulates the pathogenesis of severe forms
of malaria is supported by the association of several polymor-
phisms in the genes encoding the nitric oxide synthase (NOS)
isoforms 1 (Dhangadamajhi et al., 2009), 2 (Hobbs et al., 2002;
Trovoada et al., 2014), and 3 (Dhangadamajhi et al., 2010) with
malaria severity in human populations. Moreover, there is also
a direct correlation between the levels of NO in plasma and the
incidence of severe malaria in human populations (Anstey
et al., 1996; Trovoada et al., 2014). Based on these observations,
pharmacologic application of NO has been proposed as a sup-
portive therapy for life-threatening complications of malaria
(Hawkes et al., 2011; Yeo et al., 2013).
Here, we report that the protective effect of NO against
ECM acts via a mechanism in which NO induces the expres-
sion of HO-1 through activation of the nuclear factor erythroid
(NF-E) 2-related factor 2 (Nrf2), a member of the Cap ‘n’
Collar basic leucine zipper family of transcription factors (Itoh
et al., 1999) that regulates adaptive cellular responses to
oxidative stress (Itoh et al., 1997; Kensler et al., 2007; Suzuki
et al., 2013). CO produced via heme catabolism by HO-1
mediates the protective effects of NO against ECM. NO
and CO do not interfere with host pathogen burden, suggest-
ing that these gasotransmitters confer disease tolerance to
Plasmodium infection.RESULTS
NO Confers Disease Tolerance to Plasmodium Infection
C57BL/6 mice succumbed to ECM when inoculated with RBCs
infected with a transgenic PbA-expressing GFP under the
control of the EEF1a promoter; i.e., PbAEEF1a-GFP infection (Fig-
ure 1A). Administration of the NO donor dipropylenetriamine
NONOate (DPTA-NO) suppressed the onset of ECM (Cabrales
et al., 2011; Gramaglia et al., 2006), with maximal protection at
DPTA-NO administration starting 1–3 days before infection and
twice daily thereafter for 7 days (Figure 1A). This protective effect
was lost when DPTA-NO administration was started 1–3 days
after infection (Figure 1A). When used at a protective dosage/
schedule, DPTA-NO prevented brain microvascular congestion
(Figure 1B), BBB disruption (Figure 1B), and brain edema (Fig-
ure 1C); i.e., the hallmarks of ECM. This protective effect was
lost when DPTA-NO was administered 3 days after infection,
as assessed for brain edema (Figure 1C).
DPTA-NO administration did not modulate parasitemia (i.e.,
percentage of circulating RBCs containing PbAEEF1a-GFP para-
sites [Figure 1D]), while reducing parasite accumulation in the
brain versus vehicle-treated controls, as assessed by quantita-
tive real-time RT-PCR (Figure 1E). We asked whether NO
reduces the sequestration of mature schizonts in the brain,
using a transgenic PbA strain expressing a GFP/Luciferase
fusion protein in mature schizonts, under the control of the
AMA1 promoter; i.e., PbAAMA1-GFP/LUC. NO had no impact on
parasitemia, as quantified by the detection of Plasmodium
DNA in circulating RBCs (Figure S1A), morphological detection
of parasites in blood smears (Figure S1B), or percentage of
circulating RBCs containing mature PbAAMA1-GFP/LUC schizonts,
as detected by GFP (Figure S1C) or by luciferase (Figures 1F
and 1G) expression. NO reduced schizont sequestration in
the brain, spleen, and heart while increasing sequestration in
the lung versus vehicle-treated controls, as quantified by lucif-
erase activity (Figures 1H, S1D–S1G, and S1K). Sequestration
was not affected in liver, kidney, and fat (Figures S1H–S1K).
This suggests that whereas NO does not interfere with parasi-
temia, it reduces parasite biomass in the brain, an effect that
should contribute to suppressing the pathogenesis of ECM
(Miller et al., 2013).
DPTA-NO inhibited the accumulation of TH and TC cells in
the brain of PbAEEF1a-GFP-infected mice versus control-infected
mice receiving vehicle, as assessed by quantitative real-
time RT-PCR for Cd3e (T cells), Cd4 (TH cells), and Cd8a (TC
cells) mRNA expression (Figure 1I). This immunomodulatory
effect should also contribute to suppressing the pathogenesis
of ECM (Belnoue et al., 2002, 2008; Nitcheu et al., 2003; Ville-
gas-Mendez et al., 2012).
The Protective Effect of NO Acts via a Mechanism
Involving the Induction of HO-1 Expression
DPTA-NO administration induced the expression of Hmox1
mRNA in C57BL/6 mice, as quantified in different organs
by quantitative real-time RT-PCR (Figure 2A) (Motterlini
et al., 1996). This was associated with induction of HO
enzymatic activity, as assessed by the relative rate of bili-
verdin/bilirubin generation (Figure 2B) as well as by COCell Reports 8, 126–136, July 10, 2014 ª2014 The Authors 127
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Figure 1. NO Suppresses ECM and Confers
Disease Tolerance to Plasmodium Infection
(A) Survival of PbAEEF1a-GFP-infected C57BL/6
mice receiving DPTA-NO (50 mg/kg, twice daily,
12 hr apart) at different schedules relative to the
day of infection (day 0); i.e., from 3 to +7 (n = 9),
1 to +7 (n = 13), +1 to +10 (n = 6), and +3 to +7
(n = 7). Control mice received vehicle (PBS; n = 28).
Six independent experiments with similar trend
were performed.
(B) H&E staining of DPTA-treated (NO) and vehicle-
treated control mice at the time of ECM onset in
controls (6303).
(C) Mean microgram (mg) of Evans blue per gram
(g) of tissue ± SD in mice receiving vehicle (Veh.;
n = 12) or DPTA-NO (1/7; n = 10; 3/7; n = 5)
7 days after PbAEEF1a-GFP infection. Two inde-
pendent experiments with similar trend were per-
formed.
(D) Mean percentage of infected GFP+ RBCs ± SD
in the same mice as in (A).
(E) Mean relative number of Plasmodium 18S/
Gusb mRNA in the brain of PbAEEF1a-GFP-infected
mice receiving vehicle (n = 7) or DPTA-NO (1/7;
n = 7) ± SD. Two independent experiments with
similar trend were performed.
(F) Luciferase activity in noninfected (NI) versus
PbAAMA1-GFP/LUC-infected mice (day 7) receiving
vehicle (Veh.) or DPTA-NO (NO; 1/7). RLU,
relative light units.
(G) Mean luciferase activity ± SD in the same mice
as (F), with seven to nine mice per group. Two in-
dependent experiments with similar trend were
performed.
(H) Mean luciferase activity ± SD in brains
collected from the same mice as (F).
(I) Mean fold induction (relative to noninfected
controls) ± SD of Cd3e, Cd4, and Cd8a mRNA
normalized to Gusb mRNA, as assessed by
quantitative real-time RT-PCR in the brain of
noninfected mice (n = 7) or PbAEEF1a-GFP-infected
mice receiving vehicle (PBS; n = 7) versus DPTA-
NO (n = 7). Two independent experiments
analyzed at day 7 after infection were performed.
*p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05.
See also Figure S1.production; i.e., CO-Hb (Figure 2C). When used at a
protective dosage/schedule, DPTA-NO failed to protect
PbAEEF1a-GFP-infected HO-1-deficient (Hmox1/) mice from
succumbing to ECM (Figures 2D and 2E). Parasitemias were
indistinguishable between Hmox1+/+ versus Hmox1/ mice
receiving DPTA-NO or not (Figure 2F). This suggests that NO
confers disease tolerance to Plasmodium infection via a mech-
anism that involves the induction of HO-1 expression.
NO Inhibits Neuroinflammation via a Mechanism
Involving HO-1
NO inhibited the accumulation of activated TH and TC cells in
the brain of PbAEEF1a-GFP-infected mice, as assessed by
quantitative real-time RT-PCR for the expression of several
effector molecules involved in the pathogenesis of ECM; i.e.,
Ctla-4 (Jacobs et al., 2002), Prf (Nitcheu et al., 2003), and128 Cell Reports 8, 126–136, July 10, 2014 ª2014 The AuthorsGzmB (Haque et al., 2011) (Figure 3A). A similar inhibitory effect
was observed for other molecules involved in TH and/or TC
activation and presumably therefore driving ECM, including
Icos, Cd28, and Fas ligand (Fasl) (Figure 3A), among others
(Figure S2). This immunomodulatory effect was lost in
Hmox1/ mice (Figures 3A and S2).
NO inhibited the expression of mRNA-encoding Cd45 in
the brain of infected Hmox1+/+ mice, but not in Hmox1/
mice, confirming that NO prevents overall leukocyte accumula-
tion in the brain (Figure 3B). A similar inhibitory effect was
observed for mRNAs encoding the chemokines Mig/Cxcl9,
Cxcl10/Ip-10, and Ccl2/Mcp1, the chemokine receptor Ccr7,
the proinflammatory cytokines Tnf and Il-6, as well as the costi-
mulatory molecules Cd80 and Cd86, in PbAEEF1a-GFP-infected
Hmox1+/+ mice, but not in Hmox1/ mice (Figure 3B). NO also
inhibited the expression of other genes involved in the
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Figure 2. The Protective Effect of NOagainst
ECM Is Mediated via HO-1 Expression
(A) Mean relative number of Hmox1/Hprt mRNA
molecules ± SD in C57BL/6 mice receiving vehicle
or DPTA-NO (50 mg/kg; twice 12 hr apart; n = 5 per
group), as assessed by real-time qRT-PCR. Sam-
ples were collected 4 hr after the last DPTA-NO
administration.
(B) Mean HO activity ± SD in mice treated as in
(A) (n = 4 per group).
(C) Mean Hb concentration and percentage of
CO-Hb ± SD in whole blood of C57BL/6 mice
(n = 10) treated as in (A).
(D) Survival of PbAEEF1a-GFP-infected WT
(Hmox1+/+; n = 10) or HO-1-deficient (Hmox1/;
n = 6) C57BL/6 mice receiving DPTA-NO. Control
Hmox1+/+ mice received vehicle (PBS; n = 9). Two
independent experiments were performed.
(E) Brain edema 7 days after PbAEEF1a-GFP infection
in Hmox1+/+ (n = 5) versus Hmox1/ (n = 4) mice
receiving DPTA-NO (+;1 to +7) or Hmox1+/+ mice
receiving vehicle (; n = 7) as in (D). Edema is
expressed as mean micrograms (mg) of Evans blue
per gram (g) of tissue ± SD in one experiment.
(F) Mean percentage of infected GFP+ RBCs ± SD
in the same mice as in (D).
*p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05.pathogenesis of ECM (Figure S2). This suggests that NO inhibits
neuroinflammation associated with Plasmodium infection via a
mechanism involving HO-1.
NO and CO Restrain TH and TC Cell Activation in
Response to Plasmodium Infection
NO reduced the number of activated CD4+CD44highCD62Llow TH
cells expressing interferon g (IFNg) and CXCR3 in the spleen of
PbAEEF1a-GFP-infected mice, as compared to infected vehicle-
treated controls (Figure 4A). A similar effect was observed for
activated CD8+CD44highCD62Llow TC cells expressing GzmB
and/or IFNg (Figure 4B). NO did not reduce the total number of
splenic lymphocytes in PbAEEF1a-GFP-infected mice, including
TH and TC cells, dendritic cells, monocyte/macrophages, or
polymorphonuclear cells, as compared to vehicle-treated con-
trols (Figure S3A).
CO administration via inhalation mimicked to a large extent
the immunoregulatory effect of NO, reducing the number of
activated CD4+CD44highCD62Llow and CD4+IFNg TH cells in
the spleen of PbAEEF1a-GFP-infected mice, as compared to air-
treated controls (Figure 4C). CO did not inhibit the expression
of CXCR3 in activated TH cells (Figure 4C). CO also reduced
the number of activated CD8+CD44highCD62Llow, CD8+GzmbB+,
and CD8+IFNg+ TC cells in the spleen of PbA
EEF1a-GFP-infected
mice, as compared to air-treated controls (Figure 4D). COCell Reports 8, 126–reduced the total number of lymphocytes
and TC cells in the spleen of infected
mice, as compared to infected air-treated
controls (Figure S3B). Given that (1) NO in-
duces HO-1 (Figures 2A and 2B) and CO
production (Figure 2C) and (2) CO mimicsthe immunoregulatory effect of NO during Plasmodium infection,
we infer that this effect of NO is probably mediated via a mech-
anism involving CO. These data, however, do not prove that CO
is necessary to support the immunoregulatory effect of NO.
The Protective Effect of NO Acts via a Mechanism
Involving Nrf2
NO induces HO-1 expression in vitro (Motterlini et al., 1996) via a
mechanism involving the transcription factor Nrf2 (Naughton
etal.,2002).Weaskedwhetherasimilarmechanismoccurs invivo
to prevent the pathogenesis of ECM. Nrf2 deletion in C57BL/6
mice impaired the induction of Hmox1 mRNA in response to
DPTA-NO, as assessed in different organs by quantitative real-
time RT-PCR (Figure 5A). This correlated with lack of HO activity
(Figure 5B), demonstrating that NO induces HO-1 and raises HO
activity in vivo, via an Nrf2-dependent mechanism.
Whenadministered at a protective dosage/schedule, NO failed
to protect Nrf2/ mice from succumbing to ECM (Figure 5C).
Parasitemiaswere similar inNrf2/ versusNrf2+/+mice receiving
DPTA-NO or not (Figure 5D). Mortality of infected Nrf2/
mice receiving DPTA-NO was associated with brain edema (Fig-
ure 5E). This suggests that Nrf2 activation by NO suppresses
ECM and confers disease tolerance to Plasmodium infection.
CO administration restored the protective effect of DPTA-NO
in PbAEEF1a-GFP-infected Nrf2/ mice (Figure 5F), without136, July 10, 2014 ª2014 The Authors 129
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Figure 3. NO Inhibits Neuroinflammation via a Mechanism Involving HO-1
(A) T cell activation. Mean fold induction of mRNA expression (relative to noninfected mice) ± SD assessed by real-time qRT-PCR in the brains of noninfected
Hmox1+/+ mice (n = 7), PbAEEF1a-GFP-infected Hmox1+/+ mice receiving vehicle (; PBS; n = 7) or DPTA-NO (+; 50 mg/kg, twice daily, 12 hr apart; from days 1
to +7; n = 7) versus Hmox1/ mice receiving DPTA-NO (+; n = 3). Expression values for each gene were normalized to Gusb mRNA. Two independent ex-
periments with similar trend were performed.
(B) Neuroinflammation, determined as in (A). *p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05. Notice that n = 3 for Hmox1/ mice.
See also Figure S2.interfering with parasitemia (Figure 5G). This suggests that the
protective effect ofNOagainst ECM ismediated via amechanism
that involves CO. These data, however, do not prove that CO is
necessary to support the protective effect of Nrf2.
HO-1 Does Not Regulate NO Bioavailability during
Plasmodium Infection
DPTA-NO administration increased the concentration of the
two major end products of NO oxidation (i.e., nitrite and nitrate,
in the plasma of noninfected or PbAEEF1a-GFP-infected mice) in
comparison to vehicle-treated controls (Figure 6A). DPTA-NO
administration was also associated with the accumulation, in
the brain of PbAEEF1a-GFP-infected mice, of the end product
of the NO-regulated enzyme guanylate cyclase cyclic guano-
sine monophosphate (cGMP) (Figure 6B) (Gramaglia et al.,
2006). Concentration of nitrite/nitrate in the plasma of
PbAEEF1a-GFP-infected Hmox1/ or Nrf2/ mice was similar
to that of wild-type (WT) controls (Figure 6A). The same was
true for cGMP accumulation in the brain (Figure 6B). This sug-
gests that expression of Nrf2-regulated genes, including HO-1,
does not modulate NO bioavailability during Plasmodium infec-
tion. Moreover, this excludes that failure of NO to suppress the130 Cell Reports 8, 126–136, July 10, 2014 ª2014 The Authorspathogenesis of ECM in Hmox1/ or Nrf2/ mice is due to a
putative reduction of NO availability.
Nrf2 and HO-1 Limit the Pro-oxidant Effect of NO
Exerted on Cell-free Hb
Although NO and CO target cell-free Hb, they should act in
opposite ways, with NO propagating Hb oxidation and CO
preventing it (Hebbel et al., 1988; Pamplona et al., 2007). NO
increased the concentration of MetHb in the plasma of non-
infected as well as in PbAEEF1a-GFP-infected WT mice, as
compared to vehicle-treated controls (Figure 6C). This effect
was exacerbated in infected Hmox1/ or Nrf2/ mice versus
WT controls (Figure 6C). This suggests that regulation of HO-1
expression by Nrf2 restrains the oxidation of cell-free Hb by
NO, during Plasmodium infection.
PbAEEF1a-GFP infection was associated with the accumulation
of non-Hb-bound heme (i.e., free heme), in the plasma of WT
mice (Figure 6D). This effect was exacerbated in Hmox1/
and in Nrf2/ mice versus WT controls, receiving NO or not
(Figure 6D). This suggests that regulation of HO-1 expression
by Nrf2 restrains NO from oxidizing Hb (Figure 6C), presumably
inhibiting the release of its prosthetic heme groups during
AB
C
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Figure 4. NO and CO Restrain TH and TC Cell Activation in Response
to Plasmodium Infection
(A–D) Mean number of splenic (A) TCRb+CD4+ TH cells or (B) TCRb
+CD8+ TC
cells expressing different activation markers ± SD in noninfected mice (n = 12)
or PbAEEF1a-GFP-infected mice receiving vehicle (n = 17) versus DPTA-NO (+;
50 mg/kg, twice daily, 12 hr apart, from days 1 to 5; n = 15). Mean number of
splenic (C) TCRb+CD4+ TH cells or (D) TCRb
+CD8+ TC cells expressing different
activation markers ± SD in noninfected mice (n = 13) or PbAEEF1a-GFP-infected
mice exposed to air (n = 15) versus CO (250 ppm, from days 3 to 5.5 post-
infection; n = 15). Analyses were performed by flow cytometry 5.5 days after
infection in three independent experiments with similar trend. *p < 0.05; **p <
0.01; ***p < 0.001. n.s., p > 0.05.
See also Figure S3.Plasmodium infection, an effect that should contribute to the
protective effect of NO against ECM (Ferreira et al., 2008).
The Protective Effect of CO against ECM Acts
Independently of NO
We assessed whether the protective effect of CO against ECM
acts via a mechanism involving endogenous NO production by
different NOS. CO administration via inhalation protected
PbAEEF1a-GFP-infected mice carrying combined deletions of
Nos alleles (i.e., Nos1/Nos2/ (Figure 7A), Nos2/Nos3/ (Fig-
ure 7B), and Nos1/Nos3/ [Figure 7C]) from succumbing toECM. Similar effects were observed in Nos1/ (Figure S4A),
Nos2/ (Figure S4B), and Nos3/ (Figure S4C) mice. The pro-
tective effect of CO was associated with inhibition of brain
edema (Figures 7D and S4D), suggesting that CO is sufficient
and likely acts downstream of NO to suppress the pathogenesis
of ECM. This observation also suggests that the protective effect
of CO does not require endogenous NO production, although
this has not been established conclusively.
Time of ECM onset was delayed in mice carrying a deletion
of the neuronal Nos1 allele (i.e., Nos1/ (Figure S4A), Nos1/
Nos2/ [Figure 7A], and Nos1/Nos3/ [Figure 7C] mice) in
comparison to genotype-matched controls carrying a functional
Nos1 allele (Figures S4A, 7A, and 7C). Neither Nos2 (Nos2/)
nor Nos3 (Nos3/) deletions influenced ECM onset or parasite-
mias in comparison to genotype-matched WT controls (Figures
S4B, S4C, and 7B).
DISCUSSION
When used pharmacologically, NO (Cabrales et al., 2011; Gra-
maglia et al., 2006; Ong et al., 2013) and CO (Ferreira et al.,
2008, 2011; Pamplona et al., 2007) suppress the pathogenesis
of ECM. The mechanism(s) underlying this salutary effect and
the potential use of these gasotransmitters as adjunctive thera-
pies to treat severe forms of malaria in humans remain to be es-
tablished (Hawkes et al., 2011).
The term gasotransmitter as used hereby refers to biologic
active gaseous molecules produced physiologically (Mustafa
et al., 2009). NO is generated by the enzymatic conversion of
L-arginine and molecular oxygen to L-citrulline, catalyzed by
different NOS isoforms, whereas CO is generated through the
enzymatic conversion of heme and molecular oxygen, catalyzed
by different HO isoforms (Tenhunen et al., 1968). In contrast to
CO, NO is a labile-free radical with potentially deleterious pro-
oxidant activity (Figure 6C) (Gladwin et al., 2004) that can act
locally in the brain to promote the pathogenesis of CM. Consis-
tent with this notion, stable end products of NO accumulate in
the cerebral spinal fluid of individuals with adverse disease
outcome from CM (Weiss et al., 1998). Moreover, deletion of
the neuronal NOS isoform (i.e., Nos1, confers some level of pro-
tection against ECM [Figures 7 and S4]), suggesting that when
produced locally in the brain, NO is deleterious and promotes,
rather than protects from, ECM.
Whenappliedpharmacologically tomice,NOacts systemically
to suppress the pathogenesis of ECM (Figure 1) (Cabrales et al.,
2011; Gramaglia et al., 2006; Ong et al., 2013). This suggests that
whereas NO can act systemically to confer protection against
malaria, its bioavailability during Plasmodium infection is not suf-
ficient to afford this salutary effect. This is attributedmost likely to
NOscavenging by cell-freeHb (Patel andGladwin, 2004;Grama-
glia et al., 2006) as well as to reduction of NOS2 expression
(Weiss et al., 1994), presumably driven by cellular iron overload
(Gozzelino et al., 2012; Gozzelino and Soares, 2014). Reduced
NO bioavailability promotes brain microvascular constriction,
thus fostering the pathogenesis of ECM (Cabrales et al., 2011;
Gramaglia et al., 2006; Ong et al., 2013). NO administration com-
pensates for reduced systemic NObioavailability duringPlasmo-
dium infection, preventing the pathogenesis of ECM.Cell Reports 8, 126–136, July 10, 2014 ª2014 The Authors 131
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Figure 5. The Protective Effect of NO Is
Mediated via HO-1 Induction by Nrf2
(A) Mean number of Hmox1/Hprt mRNA
molecules ± SD in Nrf2-deficient (Nrf2/) mice
receiving vehicle or DPTA-NO (NO; 50mg/kg twice
12 hr apart; n = 5 per group), as assessed by qRT-
PCR. Samples were collected 4 hr after the last
DPTA-NO administration. The y axis scale is the
same as in Figure 2A, for comparison.
(B) HO activity is shown asmean pmol bilirubin/mg
of tissue/hr ± SD in mice treated as in (A) (n = 4
mice per group). The y axis scale is the same as in
Figure 2B, for comparison.
(C) Survival of PbAEEF1a-GFP-infected Nrf2+/+ mice
(n = 9) versus Nrf2/ mice (n = 7) receiving
DPTA-NO (NO: 50 mg/kg, twice daily, 12 hr apart,
days 1 to +7) or Nrf2+/+ mice receiving vehicle
(PBS; n = 8). Two independent experiments with
similar trend were performed.
(D) Mean percentage of infected RBCs ± SD in the
same mice as in (C).
(E) Brain edema 7 days in PbAEEF1a-GFP-infected
Nrf2+/+ mice receiving vehicle (PBS; n = 3) or
DPTA-NO (NO; +; 1 to +7) versus Nrf2/ mice
receiving DPTA-NO (+; NO; 1 to +7; n = 3).
Edema is expressed as mean micrograms (mg) of
Evans blue per gram (g) of tissue ± SD; data are
derived from one experiment.
(F) Survival of PbAEEF1a-GFP-infected Nrf2/ mice
receiving DPTA-NO (NO) and exposed to air (n = 8)
or CO (250 ppm, from days 3 to 6 postinfection;
n = 14). Two independent experiments with similar
trend were performed.
(G) Mean percentage of infected RBCs ± SD in the
same mice as in (F).
*p < 0.05; ***p < 0.001. n.s., p > 0.05.Althoughwe confirmed that NO administration suppresses the
pathogenesis of ECM (Figure 1) (Cabrales et al., 2011; Gramaglia
et al., 2006; Ong et al., 2013), we found that this protective effect
relies on the induction of HO-1 (Figure 2), via a mechanism
involving the transcription factor Nrf2 (Figure 5). Induction of
HO-1 leads to the production of CO (Figure 2) (Motterlini et al.,
1996), a gasotransmitter that suppresses the pathogenesis of
ECM (Figures 5, 7, and S4). NO acts most likely as a ‘‘double-
edged’’ sword during Plasmodium infection, promoting Hb
oxidation (Figure 6C) as well as the expression of HO-1 and the
production ofCO (Figure 2), limitingHboxidation (Figure 6D). Pre-
sumably, HO-1 and CO contribute to the protective effect of NO
(Figures 2 and 5) by suppressing Hb oxidation and heme release
from Hb, thus preventing heme from partaking in the pathogen-
esis of ECM (Ferreira et al., 2008, 2011; Pamplona et al., 2007).
These effects of HO-1 and CO, which limit the pro-oxidant effect
of NO, probably allow this gasotransmitter to exert additional
salutary effects that act irrespectively of HO-1 and CO.
NO has no apparent impact on pathogen load, suggesting that
this gasotransmitter confers disease tolerance to the blood
stage of Plasmodium infection (Figure 1). However, NO reduces
parasite sequestration in the brain (Figures 1H and S1D), a salu-
tary effect that should contribute to suppressing the onset of
ECM as well as that of CM (Miller et al., 2013). NO also inhibits
the activation, proliferation, and expansion of pathogenic TH132 Cell Reports 8, 126–136, July 10, 2014 ª2014 The Authorsand TC in the spleen during the blood stage of Plasmodium
infection (Figure 4). This prevents the accumulation of TH and
TC cells in the brain of infected mice (Figure 1), reducing neuro-
inflammation (Figure 3) and, as such, suppressing the pathogen-
esis of ECM (Miller et al., 2013). This salutary effect is probably
exerted via the pro-oxidant activity of NO, which suppresses
T cell responses (Hoffman et al., 1990) through the induction of
T cell apoptosis (Brito et al., 1999). NO may also act indirectly,
via the induction of HO-1, to induce T cell apoptosis (McDaid
et al., 2005; Soares et al., 2009).
When applied to Nos1-deficient mice (i.e., Nos1/, Nos1/
Nos2/, or Nos1/Nos3/), CO exerts a negative impact on
parasitemia (Figures S4A, 7A, and 7C). This effect is only
observed in Nos1-deficient mice, presumably because a small
fraction of these mice escapes ECM (Figures S4A, 7A, and 7C),
thus allowing for comparison of parasitemia over time. This sug-
gests that COmodulates not only disease tolerance, early during
Plasmodium infection (i.e., preventing CM without impacting on
pathogen load) but also resistance (i.e., reducing pathogen
load) later on, in comparison to control mice that do receive
CO. This latter effect of COmaybe exerted via a direct interaction
of this gasotransmitter with the pathogen or indirectly via modu-
lation of host-resistance mechanisms (Soares et al., 2009).
In conclusion, the salutary effect exerted by NO during Plas-
modium infection is mediated to at least some extent, indirectly,
A B
C D
Figure 6. HO-1 and Nrf2 Do Not Modulate NO Bioavailability during
Plasmodium Infection while Restraining Hb Oxidation and Heme
Release
(A) Mean ratio of nitrite-to-nitrate concentration ± SD in the plasma of non-
infected (NI) WT C57BL/6 mice receiving vehicle (PBS; n = 10) or DPTA-NO
(NO; 50 mg/kg twice daily, 12 hr apart from day 1 to +6: n = 10) versus
PbAEEF1a-GFP-infected WT, HO-1-deficient (Hmox1/), or Nrf2-deficient
(Nrf2/) C57BL/6 mice receiving DPTA-NO (n = 12 for WT, n = 8 forHmox1/
and n = 14 for Nrf2/) or vehicle (n = 14 for WT, n = 9 for Hmox1/ and n = 12
for Nrf2/). Three independent experiments with similar trend were per-
formed.
(B) Mean cGMP ± SD in noninfected (NI) WT C57BL/6 mice receiving vehicle
(n = 10) or DPTA-NO (NO, n = 10) versus PbAEEF1a-GFP-infectedWT,Hmox1/,
or Nrf2/ mice receiving DPTA-NO (n = 13 for WT, n = 7 for Hmox1/ mice
and n = 12 for Nrf2/mice) or vehicle (n = 14 for WT, n = 9 for Hmox1/mice
and n = 12 for Nrf2/mice). Three independent experiments were performed.
NO donor DPTA-NO was administered from day 1 to day 6 postinfection.
(C) Mean concentration of MetHb ± SD in the plasma of noninfected
or PbAEEF1a-GFP-infected mice receiving vehicle (PBS) or DPTA-NO (NO;
50 mg/kg twice daily, 12 hr apart from day 1 to +6). Measurements were
taken on day 6 postinfection. Three experiments (n = 5–12mice per group) with
similar trend were performed.
(D) Mean concentration of non-Hb-bound (free) heme ±SD in the plasma of the
same mice as in (C).
*p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05.by CO. This interplay between the two gasotransmitters should
be taken into consideration when envisioning their therapeutic
application as adjunctive therapies against severe forms of
malaria.
EXPERIMENTAL PROCEDURES
Mice
Mice were bred and maintained under specific pathogen-free (SPF) condi-
tions. Protocols were approved by the Ethics Committee of the Instituto
Gulbenkian de Cieˆncia (A008.2010 and A009.2011) and by the Portuguese
National Entity (Direc¸a˜o Geral de Alimentac¸a˜o e Veterina´ria; 008959 and
018071). All experiments were performed according to the Portuguese (De-
creto-Lei 113/2013) and European (Directive 2010/63/EU) legislations.
Parasites, Infection, and Disease Assessment
Mice were infected by intraperitoneal (i.p.) inoculation of 105 RBCs infected
with transgenic PbA strains PbAEEF1a-GFP (259cl1; MR4; MRA-865) (Franke-
Fayard et al., 2004) or PbAAMA1-GFP/LUC (1037cl1) (Spaccapelo et al., 2010).
Parasitemias were determined by flow cytometry (Ferreira et al., 2011)and/or byGiemsa-stained blood smears.Miceweremonitored daily for clinical
signs of ECM, including hemi- or paraplegia, head deviation, tendency to
rollover on stimulation, ataxia, and convulsions. The day of infection is zero
(0) in all experiments.
NO Treatment
Mice received DPTA-NO (Alexis Biochemicals) i.p. (50 mg/kg of body weight
dissolved in 200 ml of PBS) twice daily with different schedules as indicated
in the figures. DPTA-NO was prepared freshly in ice-cold PBS and injected
immediately thereafter.
CO Treatment
Mice were placed in a gastight 60-liter capacity chamber and exposed contin-
uously between days 3 and 6 postinfection to CO at a flow rate of 12 l/min
(final concentration of 250 ppm) (Sato et al., 2001). CO concentration was
monitored continuously using a CO analyzer (Interscan).
Luciferase Imaging
Mice were infected with PbAAMA1-GFP/LUC, treated with vehicle or DPTA-NO
(day 1 to +7), and luciferase activity was determined at the time of ECM
onset in control mice (i.e., day 7). Luciferase activity was visualized by
whole-mice imaging or in dissected tissues using an electron-multiplying
charge-coupled device (EM-CCD) photon-counting camera (ImagEM;
Hamamatsu).
Brain Edema
Brain edema was evaluated using Evans blue, administered intravenously (2%
solution, 100 ml; Sigma-Aldrich), as described by Pamplona et al. (2007).
HO-1 Activity
Mice were injected (i.p.) with DPTA-NO or vehicle twice 12 hr apart, and HO
activity was measured 4 hr thereafter in tissues snap-frozen in liquid nitrogen,
as described by Sato et al. (2001).
Endogenous CO Production
Mice were treated with vehicle or DPTA-NO as detailed for HO-1 activity
determination. Blood was collected from the facial vein (200 ml) into a hepa-
rinized tube (10 ml), transferred to an assay cuvette, and analyzed using an
Avoximeter 4000 (ITC) for total Hb (g/dl) and CO-Hb (percentage of total
Hb) content.
Histology
Brains were harvested when clinical signs of ECM were observed in control
mice. Tissue was fixed in buffered 4% (v/v) paraformaldehyde and embedded
in paraffin. Paraffin sections were cut at 12 mm, stained with hematoxylin and
eosin (H&E), and analyzed via an Olympus BX51 light microscope.
Quantitative Real-Time PCR
Mice were sacrificed at the day of ECM onset in control mice. Total RNA
was isolated from the different organs using TRIzol (Invitrogen Life Technol-
ogies) and the RNeasy Mini Kit (QIAGEN) and used to synthesize cDNA for
PCR with Power SYBR Green PCR master mix (Invitrogen Life Technolo-
gies). Transcript number was calculated from the threshold cycle (Ct) of
each gene with a 2DDCT method (relative number) and normalized to
hypoxanthine-guanine phosphoribosyltransferase (Hprt) or glucuronidase
b (Gusb).
Mouse Immune Quantitative RT-PCR Array
TaqMan gene signature mouse immune array (Applied Biosystems) was used
to quantify all other mRNAs according to manufacturer’s recommendations
(Ferreira et al., 2011). Gene expression was determined as above.
T Cell Activation
Analyses of T cell activation were performed in the spleens of naive or
PbAEEF1a-GFP-infected C57BL/6 mice at 5.5 days postinfection, as described
in Ferreira et al. (2011).Cell Reports 8, 126–136, July 10, 2014 ª2014 The Authors 133
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Figure 7. CO Confers Protection against
ECM in Double NOS-Deficient Mice
(A) Survival and mean parasitemia ± SD of
PbAEEF1a-GFP-infected WT (Nos1/Nos2+/+) versus
Nos1/Nos2/ mice exposed to air (n = 9 for WT;
n = 8 for Nos1/Nos2/) or CO (250 ppm, from day
3 to 6 postinfection; n = 4 for WT; n = 4 for Nos1/
Nos2/). Two independent experiments with
similar trend were performed.
(B) Survival and mean parasitemia ± SD of
PbAEEF1a-GFP-infected WT (Nos2/Nos3+/+) versus
Nos2/Nos3/mice exposed to air (n = 14 for WT;
n = 8 for Nos2/Nos3/) or CO (n = 4 for WT; n = 8
for Nos2/Nos3/). Three independent experi-
ments with similar trend were performed.
(C) Survival and mean parasitemia ± SD of
PbAEEF1a-GFP-infected WT (Nos1/Nos3+/+) versus
Nos1/Nos3/ mice exposed to air (n = 9 for WT;
n = 5 for Nos1/Nos3/) or CO (n = 4 for WT; n = 2
for Nos1/Nos3/). Two independent experiments
were performed.
(D) Brain edema quantified by Evans blue
accumulation in the brain parenchyma of
PbAEEF1a-GFP-infected WT, Nos1/Nos2/, Nos2/
Nos3/, and Nos1/Nos3/mice receiving air ()
or CO (+). Panel shows mean micrograms (mg) of
Evans blue per gram (g) of brain tissue ± SD. Two
independent experiments with similar trend were
performed. When indicated, mice received CO via
inhalation between day 3 and day 6 postinfection
(250 ppm, 24 hr/day). n = 5 mice per group.
*p < 0.05; **p < 0.01; ***p < 0.001. n.s., p > 0.05.
See also Figure S4.Statistics
Survival curves were represented as Kaplan-Meier plots, and significance was
evaluated with the log rank (Mantel-Cox) test. Comparison of the means of
three or more groups was performed using one-way ANOVA, and significance
between every two groups was assessed by the Bonferroni multiple compar-
ison test when data assumed Gaussian distribution, as assessed by the
D’Agostino and Pearson omnibus normality test. For samples with a ‘‘(n)’’
not allowing to ascertain Gaussian distribution, group comparison was
analyzed using the Kruskal-Wallis test, followed by Mann-Whitney U test for
assessment of significance between every two groups. Outliers were identified
with the Grubbs’ test from the GraphPad software, available online (http://
graphpad.com/quickcalcs/Grubbs1.cfm). All tests were performed with the
GraphPad v.5.0a software (Prism), and p values were represented as *p <
0.05, **p < 0.01, and ***p < 0.001.
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